

FierceBiotech
Presents: An Executive Breakfast

Cancer Drug R&D: Blazing a Short Path to an Accelerated Approval

June 16, 2015 • 7:15am to 8:45am • Philadelphia, PA

REGISTER TODAY!

Free Daily Pharma Industry Newsletter Every business day, *FiercePharma* updates pharmaceutical executives on the latest Pharma industry news and deals. Stay up to date on:

Pharma Company News | Generic Drug Companies | Pharmaceutical Marketing & Sales | FDA Regulations & Warnings | Phase IV Clinical Trials

[Click here](#) to see a sample.

We never sell or give away your contact information. Our readers' trust comes first.

Topics: [Sales and Marketing](#)

The top 10 best-selling multiple sclerosis drugs of 2013

September 9, 2014

SHARE

Want a surefire way to shake up a drug market? Introduce new medication options that make it easier for patients to manage their disease. MS drugmakers would know; their market is all of a sudden full of them.



Carly Helfand

 Email
Tweet

115

Share

Like
g+1

For one, a game-changing trio of pills is providing an alternative to injections. Novartis' ([\\$NVS](#)) [Gilenya](#) hit first in September 2010, followed by Sanofi's ([\\$SNY](#)) [Aubagio](#) and Biogen Idec's ([\\$BIIB](#)) [Tecfidera](#). Two of those three, [Gilenya](#) and [Tecfidera](#), nabbed spots on our list of [Top 15 drug launch superstars](#) after hitting the ground running. They're primed to keep moving up the food chain, too.

Then, there are new, long-acting meds like the 40-mg version of best-seller [Copaxone](#), which hit the market just in time for maker [Teva](#) ([\\$TEVA](#)) to start converting patients ahead of a bumped-up May patent expiration. With a Supreme Court appeal in its patent case set to begin soon, [Teva](#)'s seeing patients switch over to the new formula--injected thrice weekly, as opposed to daily--at a rate that has so far both surprised and impressed analysts. [Biogen Idec](#), too, recently snagged the FDA's favor for its own long-lasting med, a follow-up to [Avonex](#)--dubbed [Plegridy](#)--that requires injection only once every two weeks.

Drugmakers are looking for more subtle yet significant ways to make their MS meds more attractive to patients, too. Take [Biogen](#)'s [Avonex Pen](#), for instance, green-lighted by the FDA the year before last. The Massachusetts biotech billed it as the first "intramuscular autoinjector" approved for MS and one it hoped would reduce "injection anxiety" and "pain."

TOOLS

Comment

Print

Reprint

All of these factors are helping redraw the MS treatment map, and we could soon be looking at a new king on the MS throne. So quick--check out our review of how the top

Like what you're reading?

[Click here to get more news like this delivered to your inbox every](#)

JOIN 150,000+ INSIDERS SIGN UP FOR OUR NEWSLETTER

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join thousands of pharma industry leaders who get *FiercePharma* via daily email. Sign up today!

ONE TEAM FOR THE ENTIRE RACE.

[LEARN MORE](#)

COVANCE
SOLUTIONS MADE REAL

POPULAR STORIES

MOST READ | MOST SHARED

- Investors: GSK chief Witty is safe for now, but one more strike and he's out
- The legal death of Actavis' Namenda strategy spells doom for the 'hard switch'
- Pfizer could buy GSK, but would Shire or Perrigo offer better targets?
- GSK, Pfizer among Big Pharmas bailing on Chinese sales as provinces squeeze prices
- Should Pfizer snap up GSK? Well, a megadeal could speed up a split

[THE LIBRARY: WEBINAR](#)

EvaluatePharma. The best-sellers list will look different before you know it. -- Carly Helfand ([email](#) | [Twitter](#)) and Eric Palmer ([email](#) | [Twitter](#))

- | | | | |
|---|--------------------------|----|-------------------------------------|
| 1 | Copaxone | 6 | Betaseron/Betaferon |
| 2 | Avonex | 7 | Tecfidera |
| 3 | Rebif | 8 | Ampyra |
| 4 | Gilenya | 9 | H.P. Acthar Gel |
| 5 | Tysabri | 10 | Aubagio |

NEXT

Filed Under [multiple sclerosis](#)

COMMENTS

9 Comments

FiercePharma

[Login](#)

[Recommend](#)

[Share](#)

Sort by Best



Join the discussion...



Leslye Gower · 9 months ago

Huh. What poison will they think of next?

1 ^ | v · [Reply](#) · [Share](#)



Lynne Heal → [Leslye Gower](#) · a month ago

One MS drug even had furniture polish added to it

^ | v · [Reply](#) · [Share](#)



Lynne Heal · 6 months ago

Many MS drugs are deadly they all need to be scrutinised along with everyone whos promoted them. This is also why a cure for MS will never be found because too many have made trillions from MS drugs all having profits , shares and commmissions alongside very high salaries its so easy to work out whats going on in MS <http://www.newsmax.com/Health/...> <http://www.independent.co.uk/l...>

^ | v · [Reply](#) · [Share](#)



The Dame Judy Dench → [Lynne Heal](#) · 4 months ago

what treatment do you suggest we take?

^ | v · [Reply](#) · [Share](#)



Lynne Heal → [The Dame Judy Dench](#) · 4 months ago

CCSVI is whats needed it works and is NOT deadly at all here is atlast someone being sued for naysaying CCSVI and knows many more will be too <http://news.nationalpost.com/n...>

^ | v · [Reply](#) · [Share](#)



Bill Anderson → [Lynne Heal](#) · a month ago

CCSVI has been deadly, not to mention that it doesnt work

^ | v · [Reply](#) · [Share](#)



Lynne Heal → [Bill Anderson](#) · a month ago



PRESENTED BY: RHO

Interest in using electronic patient reported outcomes (ePRO) on smart devices is on the rise. In this webinar, Emily Cantrell and Becky Baggett will share lessons learned working on a large phase 3 pain study that utilizes ePRO on tablet devices. [Register Now!](#)

[MORE ITEMS](#)

FierceBiotech
Presents: An Executive Breakfast

Cancer Drug R&D: Blazing a Short Path to an Accelerated Approval

June 16, 2015 • 7:15am to 8:45am
Philadelphia, PA

[REGISTER TODAY!](#)

LATEST COMMENTARY

Teva's recent history gives Mylan chairman plenty of anti-buyout zingers

Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff

Get out your binoculars for FiercePharma's traditional holiday trend-spotting

Pfizer believes a dose of confidence will help it sell biosimilars

We publish, you pick: FiercePharma's 10 best-read stories of 2014

EVENTS

Pharmaceutical Manufacturing/Processing Equipment & Packaging for Sale

Sensors Expo & Conference
June 9-11 — Long Beach, CA

BIO International Convention
June 15-18, 2015 — Pennsylvania Convention Center

[MORE EVENTS](#)

2015 LIFE SCIENCES
PROMOTIONAL CONTENT
MANAGEMENT SURVEY

[COMPLETE THE SURVEY TODAY!](#)

An Executive
Breakfast

**Cancer Drug R&D:
Blazing a Short
Path to an
Accelerated
Approval**

June 16, 2015



painkills2 · 9 months ago

In 2014, will the list include Sativex?

^ | v · Reply · Share ›



Lynne Heal → painkills2 · 4 months ago

Sativex is not like MS drugs this drug helps the pain yet denied. Its so easy to work out whats really going on in MS

1 ^ | v · Reply · Share ›

ALSO ON FIERCEPHARMA

WHAT'S THIS?

German cost watchdogs look askance at uniQure's \$1.4M gene ...

2 comments · 6 days ago

Avatar **DrMedValue** — May I ask you to redo your homework and consult a German reimbursement specialist before you ...

With U.S. sales suffering, GSK plots changes to quota-free pay model

1 comment · a month ago

Avatar **lbhajdu1** — GSK is paying under the table kickbacks to Richard Pan. I think that needs investigation. They stand ...

Study says no good has come from FDA's action on gout drug colchicine

1 comment · 2 months ago

Avatar **Michael A. Swit** — Please note that FDA has had the power to regulate the safety of drugs since 1938 when the ...

GSK shingles shot might trump Merck's Zostavax, analysts say

2 comments · 2 months ago

Avatar **Tammi Apodoca** — I'm 35 years old female and I tested positive for herpes type 2 in 2010. I did get bad ...

Subscribe Add Disqus to your site Privacy

PRESS RELEASES

Quintiles Launches New Solution to Meet Needs of Asia-Pacific Emerging Biopharmaceutical Companies

Myomo, Inc. Partners with Paralyzed Veterans of America

Study Shows Sorin Group's Phospholipid Reduction Treatment Significantly Reduces Calcium Absorption in Tissue Heart Valves to Help Enhance Valve Durability

Bayer has outstanding perspectives as a pure Life Science company

UMD Researcher Developing Virtual "CyberHeart" for Testing & Improving Implantable Cardiac Devices

[More Press Releases](#)

FEATURED JOBS

> Need a job? Need to hire? Visit our jobs site.

A publication of

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get *FiercePharma* via daily email. [Click here](#) to get your free weekly email briefing today!

The FierceMarkets Network:

- Telecom**
- FierceCable
- FierceDeveloper
- FierceWireless:Europe
- FierceWirelessTech
- FierceOnlineVideo
- FierceTelecom
- FierceWireless

- Marketing & Retail**
- FierceCMO
- FierceMobileMarketer
- FierceRetail
- FierceRetailIT
- FierceMobileRetail

- Healthcare**
- FierceEMR
- FierceHealthcare
- FierceHealthFinance
- FierceHealthIT
- FierceHealthPayer
- FierceHealthPayerAntiFraud
- FierceMobileHealthcare
- FiercePracticeManagement
- Hospital Impact

- Government**
- FierceGovernment
- FierceGovernmentIT
- FierceHomelandSecurity
- FierceMobileGovernment
- FierceCities
- FierceGovHealthIT

- Life Sciences**
- FierceBiotechResearch
- FierceBiotech
- FierceBiotechIT
- FierceCRO
- FierceDiagnostics
- FierceDrugDelivery
- FierceMedicalDevices
- FiercePharma
- FiercePharmaAsia
- FiercePharmaManufacturing
- FiercePharmaMarketing
- FierceVaccines
- FierceAnimalHealth

- Enterprise IT**
- FierceBigData
- FierceCIO
- FierceContentManagement
- FierceDevOps
- FierceEnterpriseCommunication
- FierceITSecurity
- FierceMobileIT

- Energy**
- FierceEnergy
- SmartGridNews

- Finance**
- FierceCFO
- FierceFinanceIT

